Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,532,241

« Back to Dashboard
Patent 5,532,241 protects VIIBRYD and is included in one NDA. There has been one Paragraph IV challenge on VIIBRYD. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has thirty-one patent family members in nineteen countries.

Summary for Patent: 5,532,241

Title: Piperidines and piperazines
Abstract:Piperidine and piperazine derivatives of the formula I ##STR1## wherein Ind is an indol-3-yl radical which is unsubstituted or mono- or polysubstituted by OH, OA, CN, Hal, COR.sup.2 or CH.sub.2 R.sup.2, R.sup.1 is benzofuran-5-yl or 2,3-dihydrobenzofuran-5-yl, chroman-6-yl, chroman-4-on-6-yl, 3-chromen-6-yl or chromen-4-on-6-yl, which is unsubstituted or monosubstituted by CN, CH.sub.2 OH, CH.sub.2 OA or COR.sup.2, Q is C.sub.m H.sub.2m, N or CR.sup.3, A is alkyl having 1-6 C atoms, Hal is F, C1, Br or I, R.sup.2 is OH, OA, NH.sub.2, NHA or NA.sub.2, R.sup.3 is H, OH or OA and m is 2, 3 or 4, and their physiologically acceptable salts, are active on the central nervous system.
Inventor(s): Bottcher; Henning (Darmstadt, DE), Seyfried; Christoph (Seeheim-Jugenheim, DE), Bartoszyk; Gerd (Darmstadt, DE), Greiner; Hartmut (Darmstadt, DE)
Assignee: Merck Patent Gesellschaft mit beschrankter Haftung (Darmstadt, DE)
Application Number:08/314,734
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Forest Labs Llc
vilazodone hydrochloride
TABLET;ORAL022567-001Jan 21, 2011RXYes5,532,241► subscribeYY
Forest Labs Llc
vilazodone hydrochloride
TABLET;ORAL022567-002Jan 21, 2011RXNo5,532,241► subscribeYY
Forest Labs Llc
vilazodone hydrochloride
TABLET;ORAL022567-003Jan 21, 2011RXNo5,532,241► subscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,532,241

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany43 33 254.4Sep 30, 1993

International Patent Family for Patent: 5,532,241

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria153663► subscribe
Australia679774► subscribe
Australia7424494► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.